StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Travere Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $92.70M. For fiscal 2026 it was $37.78M. The highest annual figure on record is $37.78M in fiscal 2026.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Dec 31, 2025$37.78M–
FY2025Dec 31, 2024-$237.48M–
FY2024Dec 31, 2023-$280.02M–
FY2023Dec 31, 2022-$186.29M–
FY2022Dec 31, 2021-$14.79M–
FY2021Dec 31, 2020-$42.74M–
FY2020Dec 31, 2019-$58.21M–
FY2019Dec 31, 2018-$24.96M-437.1%
FY2018Dec 31, 2017$7.40M–
FY2017Dec 31, 2016-$3.44M–
FY2016Dec 31, 2015-$1.39M–
FY2015Dec 31, 2014-$45.85M–
FY2014Dec 31, 2013-$17.59M–
FY2012Feb 29, 2012-$49–
FY2011Feb 28, 2011-$689–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$58.07M+1065.4%
Q1 FY2027Mar 31, 2026-$40.37M–
Q4 FY2026Dec 31, 2025$60.68M–
Q3 FY2026Sep 30, 2025$14.32M–
Q2 FY2026Jun 30, 2025$4.98M–
Q1 FY2026Mar 31, 2025-$42.19M–
Q4 FY2025Dec 31, 2024-$35.72M–
Q3 FY2025Sep 30, 2024-$42.51M–
Q2 FY2025Jun 30, 2024-$40.24M–
Q1 FY2025Mar 31, 2024-$119.01M–
Q4 FY2024Dec 31, 2023-$70.47M–
Q3 FY2024Sep 30, 2023-$59.13M–
Q2 FY2024Jun 30, 2023-$69.30M–
Q1 FY2024Mar 31, 2023-$81.12M–
Q4 FY2023Dec 31, 2022-$54.64M–
Q3 FY2023Sep 30, 2022-$39.53M-223.3%
Q2 FY2023Jun 30, 2022-$36.81M-666.6%
Q1 FY2023Mar 31, 2022-$55.32M–
Q4 FY2022Dec 31, 2021-$26.88M–
Q3 FY2022Sep 30, 2021$32.06M+376.1%
Q2 FY2022Jun 30, 2021$6.50M–
Q1 FY2022Mar 31, 2021-$26.47M–
Q4 FY2021Dec 31, 2020-$13.87M–
Q3 FY2021Sep 30, 2020$6.74M–
Q2 FY2021Jun 30, 2020-$6.45M–
Q1 FY2021Mar 31, 2020-$29.16M–
Q4 FY2020Dec 31, 2019-$4.49M–
Q3 FY2020Sep 30, 2019-$14.12M–
Q2 FY2020Jun 30, 2019-$19.11M–
Q1 FY2020Mar 31, 2019-$20.49M–
Q4 FY2019Dec 31, 2018-$3.57M–
Q3 FY2019Sep 30, 2018-$3.90M-162.9%
Q2 FY2019Jun 30, 2018-$2.76M-150.5%
Q1 FY2019Mar 31, 2018-$14.73M–
Q4 FY2018Dec 31, 2017-$854.00K–
Q3 FY2018Sep 30, 2017$6.20M+33.9%
Q2 FY2018Jun 30, 2017$5.47M–
Q1 FY2018Mar 31, 2017-$3.41M–
Q4 FY2017Dec 31, 2016-$8.49M–
Q3 FY2017Sep 30, 2016$4.63M–

More Travere Therapeutics figures

See a number that looks wrong?